Partnered with Sam Chun Dang Pharm (SCD), JGL is starting the registration of Aqua Maris products in BoV forms for adults and children (150 ml) on the South Korean market.
Our company is recognized as an EU company with great technological potential, and the spread of international presence on the Asian continent also marks the opening of the seventh market of JGL’s strategic region.
SCD is a company that was founded in 1943, and in 2016, it recorded a revenue of $ 125 million, an increase of 11 percent compared to the previous year. Most of its revenue comes from the domestic market of South Korea, and along with the production of eye drops, tablets, capsules and ampoules, the company distributes and exports drugs.
Our Aqua Maris is becoming a part of its ENT or respiratory segment, which until now has consisted of cough syrups, anti-allergy and asthma drugs.
Over the past few months, JGL’s presence has also increased in the ASEAN region, one of the key strategic regions of growth.
In partnership with Favorex, the registration procedure for Aqua Maris products was launched for the Philippine market, which is also the sixth territory of the ASEAN region. The launch plan and the placement of the first order of Aqua Maris products in the Philippines is planned for the beginning of 2018. Additionally, the expansion of the portfolio in current ASEAN markets, through the extension of Aqua Maris and the introduction of the Meralys line, is being further considered.